Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04914286




Registration number
NCT04914286
Ethics application status
Date submitted
31/05/2021
Date registered
4/06/2021
Date last updated
12/03/2024

Titles & IDs
Public title
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Scientific title
A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid Tumors
Secondary ID [1] 0 0
GFH018X0201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumor 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GFH018
Treatment: Drugs - Toripalimab

Experimental: GFH018+Toripalimab - Patient will be dosed in GFH018 in combination with Toripalimab. In the PhaseIb part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the Phase II part, patients will be assigned based on tumor type(s).


Treatment: Drugs: GFH018
Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.

Treatment: Drugs: Toripalimab
Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Phase Ib:Incidence of dose-limiting toxicity (DLT) events
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Phase II: ORR (Objective Response Rate)
Timepoint [2] 0 0
approximately 6 months after first dose

Eligibility
Key inclusion criteria
1. Has histologically or cytologically confirmed diagnosis of advanced or metastatic
solid tumors, progressed on at least first line therapy.

2. Has sufficient organ functions.

3. Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) = 1. Subject with
tumor involvement of the liver must have the Child-Pugh score of 0-7.

4. Life expectancy=12 weeks.

5. Female or male subjects of child-bearing potential must agree to use effective
contraceptive methods from the signing of the informed consent to 90 days after the
last administration of the study drug. Fertile female subjects must have negative
pregnancy test results within 7 days (inclusive) before administration.

In addition, eligible patients in phase II part must meet the following criteria:

1. Histologically or cytologically confirmed diagnosis of unresectable or metastatic
advanced tumors of specific types: hepatocellular carcinoma,
cholangiocarcinoma/gallbladder cancer (except carcinoma of ampulla), pancreatic
cancer, colorectal cancer, urothelium carcinoma, cervical cancer, head and neck
squamous cell carcinoma, esophageal cancer and nasopharyngeal carcinoma.

2. At least one measurable lesion (according to RECIST 1.1).
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Impaired cardiac function or clinically significant cardiac diseases.

2. With acute or chronic infections.

3. With active central nervous system metastases, including symptomatic brain metastases,
meningeal metastases, spinal cord compression, or requiring treatment with
glucocorticoids, antiepileptic drugs, anticonvulsant drugs, or mannitol.

4. With known active autoimmune diseases or a history of autoimmune diseases within 1
year prior to enrollment.

5. With clinically significant gastrointestinal diseases.

6. Uncontrollable or symptomatic ascites, pleural effusion or pericardial effusion.

7. With previous or present interstitial pneumonia.

8. With other uncontrolled systemic diseases, such as hypertension and diabetes.

9. Diagnosed with other malignant tumors within 3 years prior to starting study drug,
except for cured carcinoma in situ of cervix and skin basal cell carcinoma.

10. With diseases requiring immunosuppressant therapy, or requiring prednisone > 10 mg/day
or equivalent dose of similar drugs during the study period.

11. Subjects who have been treated with immunosuppressant drugs within 28 days prior to
starting study drug, except for topical and inhaled cortisol and systemic cortisol of
physiological dose (prednisone < 10 mg/day or equivalent dose of similar drugs).

12. Subjects who have received live vaccine, attenuated vaccine within 28 days prior to
starting study drug, or plans to receive live vaccine, attenuated vaccine during
treatment or within 30 days after the last administration.

13. Subjects who have been treated with radiotherapy, chemotherapy, targeted therapy,
endocrine therapy, immunotherapy, and other anti-tumor therapies, or other
investigational drugs within 5 half-life periods or within 28 days (whichever is
shorter) prior to starting study drug.

14. Subject who has received major surgeries (except for needle biopsy) that may affect
the administration or study evaluation within 28 days prior to starting study drug.

15. Subjects who have received strong inhibitor or inducer of CYP3A4, or herbal
medicine/traditional Chinese medicines within 5 half-life periods or within 2 weeks
(whichever is shorter) prior to starting study drug.

16. Subjects who have received combined treatment of drugs targeting TGF-ß and PD-(L)1,
including combination of antibody and small molecule or bispecific antibody.

17. Pregnant or lactating women.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/10/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
31/12/2023
Sample size
Target
Accrual to date
Final
148
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Linear Clinical Research Ltd - Perth
Recruitment postcode(s) [1] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
China
State/province [1] 0 0
Guangdong
Country [2] 0 0
China
State/province [2] 0 0
Shanghai

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Zhejiang Genfleet Therapeutics Co., Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and
preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced
solid tumors.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04914286
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries